Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Bevacizumab (Primary) ; Sintilimab (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms INOVA
- 13 Aug 2024 Status changed from recruiting to completed.
- 07 May 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2022).
- 13 Sep 2022 Results (n=23; Between April 8, 2021 and April 25, 2022 (data cutoff)) assessing the potential benefit of sintilimab plus bevacizumab combination therapy for recurrent/persistent ovarian clear cell carcinoma patients, presented at the 47th European Society for Medical Oncology Congress.